{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:07:01Z","timestamp":1780762021655,"version":"3.54.1"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005780","name":"Chitkara University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.intimp.2023.110845","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T10:20:52Z","timestamp":1694168452000},"page":"110845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"PA","title":["Nuclear orphan receptors: A novel therapeutic agent in neuroinflammation"],"prefix":"10.1016","volume":"124","author":[{"given":"Kiran","family":"Thakur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarjot Kaur","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.110845_b0005","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12253-018-0440-6","article-title":"Orphan nuclear receptors in colorectal cancer","volume":"24","author":"Kelly","year":"2018","journal-title":"Pathol. Oncol. Res."},{"issue":"11\u201312","key":"10.1016\/j.intimp.2023.110845_b0010","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.drudis.2007.04.006","article-title":"Orphan nuclear receptors in drug discovery","volume":"12","author":"Shi","year":"2007","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0015","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1038\/s41598-017-10202-7","article-title":"Characterization of a new pathway that activates lumisterol in vivo to biologically active hydroxylumisterols","volume":"7","author":"Slominski","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0020","doi-asserted-by":"crossref","first-page":"nrs-07003","DOI":"10.1621\/nrs.07003","article-title":"Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism","volume":"7","author":"Jetten","year":"2009","journal-title":"Nucl. Recept. Signal."},{"issue":"7","key":"10.1016\/j.intimp.2023.110845_b0025","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1096\/fj.13-242040","article-title":"ROR\u03b1 and ROR \u03b3 are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy-and 20, 23-dihydroxyvitamin D","volume":"28","author":"Slominski","year":"2014","journal-title":"FASEB J."},{"issue":"9","key":"10.1016\/j.intimp.2023.110845_b0030","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s12031-021-01841-7","article-title":"Traumatic brain injury: mechanistic insight on pathophysiology and potential therapeutic targets","volume":"71","author":"Thapa","year":"2021","journal-title":"J. Mol. Neurosci."},{"issue":"108","key":"10.1016\/j.intimp.2023.110845_b0035","article-title":"Intervention of neuroinflammation in the traumatic brain injury trajectory: In vivo and clinical approaches","volume":"1","author":"Prabhakar","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2023.110845_b0040","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/diagnostics10070483","article-title":"Cardiovascular risk and statin therapy considerations in women","volume":"10","author":"Gheorghe","year":"2020","journal-title":"Diagnostics."},{"key":"10.1016\/j.intimp.2023.110845_b0045","first-page":"1","article-title":"Adenosine as a Key Mediator of Neuronal Survival in Cerebral Ischemic Injury","volume":"30","author":"Khan","year":"2022","journal-title":"Neurochem. Res."},{"issue":"110","key":"10.1016\/j.intimp.2023.110845_b0050","article-title":"Caspase-mediated regulation of the distinct signaling pathways and mechanisms in neuronal survival","volume":"1","author":"Khan","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"106","key":"10.1016\/j.intimp.2023.110845_b0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0065-2776(10)06002-5","article-title":"Nuclear receptors, inflammation, and neurodegenerative diseases","volume":"1","author":"Saijo","year":"2010","journal-title":"Adv. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110845_b0060","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s11064-021-03521-9","article-title":"Calpain inhibitors as potential therapeutic modulators in neurodegenerative diseases","volume":"47","author":"Khan","year":"2022","journal-title":"Neurochem. Res."},{"issue":"267","key":"10.1016\/j.intimp.2023.110845_b0065","article-title":"Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases","volume":"15","author":"Thapa","year":"2021","journal-title":"Life Sci."},{"issue":"491","key":"10.1016\/j.intimp.2023.110845_b0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuroscience.2022.03.016","article-title":"Pharmacological Postconditioning by Protocatechuic Acid Attenuates Brain Injury in Ischemia-Reperfusion (I\/R) Mice Model: Implications of Nuclear Factor Erythroid-2-Related Factor Pathway","volume":"21","author":"Khan","year":"2022","journal-title":"Neuroscience"},{"issue":"12","key":"10.1016\/j.intimp.2023.110845_b0075","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.3390\/molecules26123724","article-title":"Role of monoamine oxidase activity in Alzheimer\u2019s disease: an insight into the therapeutic potential of inhibitors","volume":"26","author":"Behl","year":"2021","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.intimp.2023.110845_b0080","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/ijms22031413","article-title":"Multifaceted role of matrix metalloproteinases in neurodegenerative diseases: Pathophysiological and therapeutic perspectives","volume":"22","author":"Behl","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2023.110845_b0085","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1124\/pr.58.4.10","article-title":"International union of pharmacology. LXVI. Orphan nuclear receptors","volume":"58","author":"Benoit","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2023.110845_b0090","first-page":"904","article-title":"Pharmacological preconditioning of the brain: a possible interplay between opioid and calcitonin gene related peptide transduction systems","volume":"60","author":"Rehni","year":"2008","journal-title":"Pharmacol. Rep."},{"issue":"5","key":"10.1016\/j.intimp.2023.110845_b0095","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3181\/0708-MR-231","article-title":"Nuclear receptors and inflammatory diseases","volume":"233","author":"Wang","year":"2008","journal-title":"Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bbrc.2019.08.008","article-title":"NR4A1 regulates cerebral ischemia-induced brain injury by regulating neuroinflammation through interaction with NF-\u03baB\/p65","volume":"518","author":"Zhang","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41419-019-2196-7","article-title":"The orphan nuclear receptor Nr4a1 mediates perinatal neuroinflammation in a murine model of preterm labor","volume":"11","author":"Estrada","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2023.110845_b0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.mito.2021.03.009","article-title":"Reviving mitochondrial bioenergetics: A relevant approach in epilepsy","volume":"58","author":"Singh","year":"2021","journal-title":"Mitochondrion"},{"issue":"11","key":"10.1016\/j.intimp.2023.110845_b0115","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1007\/s11064-021-03402-1","article-title":"Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-\u0263): Molecular Effects and Its Importance as a Novel Therapeutic Target for Cerebral Ischemic Injury","volume":"46","author":"Mannan","year":"2021","journal-title":"Neurochem. Res."},{"issue":"20","key":"10.1016\/j.intimp.2023.110845_b0120","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1101\/gad.12.20.3149","article-title":"Orphan nuclear receptors\u2014new ligands and new possibilities","volume":"12","author":"Blumberg","year":"1998","journal-title":"Genes Dev."},{"issue":"749","key":"10.1016\/j.intimp.2023.110845_b0125","article-title":"Therapies modulating insulin resistance in Parkinson's disease: A cross talk","volume":"1","author":"Sharma","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.intimp.2023.110845_b0130","article-title":"Therapeutic Insights on Ferroptosis in Parkinson's disease","volume":"2","author":"Thapa","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110845_b0135","first-page":"2011","article-title":"Do PPAR-gamma agonists have a future in Parkinson's disease therapy?","volume":"1","author":"Carta","year":"2011","journal-title":"Parkinson\u2019s disease."},{"issue":"262","key":"10.1016\/j.intimp.2023.110845_b0140","article-title":"Insulin resistance and bioenergetic manifestations: Targets and approaches in Alzheimer's disease","volume":"1","author":"Sharma","year":"2020","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.intimp.2023.110845_b0145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/156720507780362092","article-title":"Therapeutic use of agonists of the nuclear receptor PPAR\u03b3 in Alzheimer's disease","volume":"4","author":"Landreth","year":"2007","journal-title":"Curr. Alzheimer Res."},{"issue":"5","key":"10.1016\/j.intimp.2023.110845_b0150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/1389450120666191017114735","article-title":"Navigating Alzheimer's Disease via Chronic Stress: The Role of Glucocorticoids","volume":"21","author":"Sharma","year":"2020","journal-title":"Curr. Drug Targets"},{"issue":"3","key":"10.1016\/j.intimp.2023.110845_b0155","first-page":"57","article-title":"Future prospect of nanotechnology in development of anti-ageing formulations","volume":"4","author":"Sharma","year":"2012","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.intimp.2023.110845_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10787-013-0195-3","article-title":"Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disorders","volume":"22","author":"Khan","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.intimp.2023.110845_b0165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1753944708090924","article-title":"PPARs as new therapeutic targets for the treatment of cerebral ischemia\/reperfusion injury","volume":"2","author":"Collino","year":"2008","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"219","key":"10.1016\/j.intimp.2023.110845_b0170","article-title":"PPAR\u03b3\/PGC1\u03b1 signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders","volume":"1","author":"Jamwal","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2023.110845_b0175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.brainresbull.2011.03.011","article-title":"Protective effect of pioglitazone, a PPAR\u03b3 ligand, in a 3 nitropropionic acid model of Huntington's disease","volume":"85","author":"Napolitano","year":"2011","journal-title":"Brain Res. Bull."},{"issue":"20","key":"10.1016\/j.intimp.2023.110845_b0180","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/hmg\/ddq322","article-title":"Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma","volume":"19","author":"Chiang","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.intimp.2023.110845_b0185","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/418765","article-title":"Peroxisome Proliferator-Activated Receptor-in Amyotrophic Lateral Sclerosis and Huntington's Disease","volume":"2008","author":"Kiaei","year":"2008","journal-title":"PPAR Res."},{"issue":"34","key":"10.1016\/j.intimp.2023.110845_b0190","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.1523\/JNEUROSCI.2038-05.2005","article-title":"The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice","volume":"25","author":"Sch\u00fctz","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.intimp.2023.110845_b0195","first-page":"12","article-title":"Nr4a family genes: A review of comprehensive prognostic and gene expression profile analysis in breast cancer. Frontiers","author":"Yousefi","year":"2022","journal-title":"Oncology"},{"issue":"157","key":"10.1016\/j.intimp.2023.110845_b0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsbmb.2015.04.016","article-title":"Nuclear receptor 4A (NR4A) family\u2013orphans no more","volume":"1","author":"Safe","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.intimp.2023.110845_b0205","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s43440-021-00258-8","article-title":"Mechanistic insight on the role of leukotriene receptors in ischemic\u2013reperfusion injury","volume":"73","author":"Khan","year":"2021","journal-title":"Pharmacol. Rep."},{"issue":"9","key":"10.1016\/j.intimp.2023.110845_b0210","doi-asserted-by":"crossref","first-page":"8107","DOI":"10.18632\/aging.103128","article-title":"Nur77 attenuates inflammatory responses and oxidative stress by inhibiting phosphorylated I\u03baB-\u03b1 in Parkinson\u2019s disease cell model","volume":"12","author":"Yan","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"6","key":"10.1016\/j.intimp.2023.110845_b0215","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.biopsych.2006.04.023","article-title":"Nur77 gene knockout alters dopamine neuron biochemical activity and dopamine turnover","volume":"60","author":"Gilbert","year":"2006","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11658-020-00241-w","article-title":"The nuclear receptor 4A family members: mediators in human disease and autophagy","volume":"25","author":"Chen","year":"2020","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0225","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.nbd.2009.07.017","article-title":"Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid","volume":"36","author":"Mahmoudi","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2023.110845_b0230","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.gendis.2018.04.008","article-title":"The effect of NR4A1 on APP metabolism and tau phosphorylation","volume":"5","author":"Zhao","year":"2018","journal-title":"Genes & Diseases."},{"key":"10.1016\/j.intimp.2023.110845_b0235","doi-asserted-by":"crossref","first-page":"e050707","DOI":"10.1002\/alz.050707","article-title":"Memory improvement effects of Ganoderma mediosinense in mice via its anticholinergic and antioxidant activities","volume":"17","author":"Singh","year":"2021","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cell.2009.01.038","article-title":"A Nurr1\/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death","volume":"137","author":"Saijo","year":"2009","journal-title":"Cell"},{"issue":"56","key":"10.1016\/j.intimp.2023.110845_b0245","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1007\/s12035-019-1487-4","article-title":"Molecular insights into NR4A2 (Nurr1): an emerging target for neuroprotective therapy against neuroinflammation and neuronal cell death","volume":"15","author":"Jakaria","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.intimp.2023.110845_b0250","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00011-015-0871-4","article-title":"Nurr1 reduction influences the onset of chronic EAE in mice","volume":"64","author":"Montarolo","year":"2015","journal-title":"Inflamm. Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0255","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.1038\/ncomms9437","article-title":"Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation","volume":"6","author":"Raveney","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2023.110845_b0260","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/NDT.S265601","article-title":"NR4A2 exacerbates cerebral ischemic brain injury via modulating microRNA-652\/Mul1 pathway","volume":"6","author":"Liu","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"16","key":"10.1016\/j.intimp.2023.110845_b0265","doi-asserted-by":"crossref","first-page":"e202200259","DOI":"10.1002\/cmdc.202200259","article-title":"Druggability Evaluation of the Neuron Derived Orphan Receptor (NOR-1) Reveals Inverse NOR-1 Agonists","volume":"17","author":"Zaienne","year":"2022","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.intimp.2023.110845_b0270","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/aps.2011.210","article-title":"Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets","volume":"33","author":"Tang","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"issue":"98","key":"10.1016\/j.intimp.2023.110845_b0275","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.biopha.2017.12.056","article-title":"Orphan G protein-coupled receptors: The role in CNS disorders","volume":"1","author":"Alavi","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"16","key":"10.1016\/j.intimp.2023.110845_b0280","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.3390\/molecules26164998","article-title":"Curcumin nanoparticles as promising therapeutic agents for drug targets","volume":"26","author":"Chopra","year":"2021","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.intimp.2023.110845_b0285","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.neubiorev.2007.01.004","article-title":"A conductor hidden in the orchestra? Role of the habenular complex in monoamine transmission and cognition","volume":"31","author":"Lecourtier","year":"2007","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"5916","key":"10.1016\/j.intimp.2023.110845_b0290","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1126\/science.1160649","article-title":"The orphan G protein\u2013coupled receptor 3 modulates amyloid-beta peptide generation in neurons","volume":"323","author":"Thathiah","year":"2009","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.intimp.2023.110845_b0295","doi-asserted-by":"crossref","first-page":"e74680","DOI":"10.1371\/journal.pone.0074680","article-title":"Gpr3 stimulates A\u03b2 production via interactions with APP and \u03b2-arrestin2","volume":"8","author":"Nelson","year":"2013","journal-title":"PLoS One"},{"issue":"40","key":"10.1016\/j.intimp.2023.110845_b0300","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2204828119","article-title":"G protein\u2013biased GPR3 signaling ameliorates amyloid pathology in a preclinical Alzheimer\u2019s disease mouse model","volume":"119","author":"Huang","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2023.110845_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.mito.2022.08.001","article-title":"Mitochondrial dynamics related neurovascular approaches in cerebral ischemic injury","author":"Khan","year":"2022","journal-title":"Mitochondrion"},{"issue":"14","key":"10.1016\/j.intimp.2023.110845_b0310","doi-asserted-by":"crossref","first-page":"10506","DOI":"10.1074\/jbc.M700911200","article-title":"Neural expression of G protein-coupled receptors GPR3, GPR6, and GPR12 up-regulates cyclic AMP levels and promotes neurite outgrowth","volume":"282","author":"Tanaka","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2023.110845_b0315","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1742-7843.2008.00276.x","article-title":"Tramadol-induced seizurogenic effect: a possible role of opioid-dependent \u03b3-aminobutyric acid inhibitory pathway","volume":"103","author":"Rehni","year":"2008","journal-title":"Basic Clin. Paharmacol. Toxicol."},{"issue":"68","key":"10.1016\/j.intimp.2023.110845_b0320","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.nbd.2014.04.007","article-title":"Developmental expression of GPR3 in rodent cerebellar granule neurons is associated with cell survival and protects neurons from various apoptotic stimuli","volume":"1","author":"Tanaka","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2023.110845_b0325","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1139\/cjpp-2019-0188","article-title":"Effects of resveratrol postconditioning on cerebral ischemia in mice: role of the sirtuin-1 pathway","volume":"97","author":"Grewal","year":"2019","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110845_b0330","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3390\/genes11060694","article-title":"Orphan G protein coupled receptors in affective disorders","volume":"11","author":"Watkins","year":"2020","journal-title":"Genes"},{"issue":"11","key":"10.1016\/j.intimp.2023.110845_b0335","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0898-6568(02)00041-4","article-title":"Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors","volume":"14","author":"Uhlenbrock","year":"2002","journal-title":"Cell. Signal."},{"issue":"2","key":"10.1016\/j.intimp.2023.110845_b0340","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1515\/revneuro-2020-0070","article-title":"CNS implications of COVID-19: a comprehensive review","volume":"32","author":"Nagu","year":"2021","journal-title":"Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0345","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/03602532.2018.1428616","article-title":"Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12","volume":"50","author":"Morales","year":"2018","journal-title":"Drug Metab. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0350","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1074\/jbc.M112.400168","article-title":"C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-\u03b2 neurotoxicity","volume":"288","author":"Benoit","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.intimp.2023.110845_b0355","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","article-title":"Regional and cellular gene expression changes in human Huntington's disease brain","volume":"15","author":"Hodges","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0360","doi-asserted-by":"crossref","first-page":"42875","DOI":"10.1038\/srep42875","article-title":"Altered enhancer transcription underlies Huntington\u2019s disease striatal transcriptional signature","volume":"7","author":"Le Gras","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-021-00232-7","article-title":"Ecto-GPR37: A potential biomarker for Parkinson\u2019s disease","volume":"10","author":"Morat\u00f3","year":"2021","journal-title":"Transl. Neurodegener."},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0370","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jnc.13109","article-title":"The role of parkinson's disease-associated receptor GPR 37 in the hippocampus: functional interplay with the adenosinergic system","volume":"134","author":"Lopes","year":"2015","journal-title":"J. Neurochem."},{"issue":"27","key":"10.1016\/j.intimp.2023.110845_b0375","doi-asserted-by":"crossref","first-page":"10189","DOI":"10.1073\/pnas.0403661101","article-title":"Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37\/parkin-associated endothelin-like receptor","volume":"101","author":"Marazziti","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2023.110845_b0380","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.3390\/ijms23074028","article-title":"Emerging Roles for the Orphan GPCRs, GPR37 and GPR37 L1, in Stroke Pathophysiology","volume":"23","author":"Mouhi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2023.110845_b0385","doi-asserted-by":"crossref","first-page":"10680","DOI":"10.1096\/fj.201900070R","article-title":"Protective effects of GPR37 via regulation of inflammation and multiple cell death pathways after ischemic stroke in mice","volume":"33","author":"McCrary","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2023.110845_b0390","first-page":"1","article-title":"Mechanistic insight on autophagy modulated molecular pathways in cerebral ischemic injury: from preclinical to clinical perspective","volume":"1","author":"Kalra","year":"2022","journal-title":"Neurochem. Res."},{"issue":"24","key":"10.1016\/j.intimp.2023.110845_b0395","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.3390\/molecules26247643","article-title":"Preclinical investigation in neuroprotective effects of the GPR55 ligand VCE-006.1 in experimental models of Parkinson\u2019s disease and amyotrophic lateral sclerosis","volume":"26","author":"Burgaz","year":"2021","journal-title":"Molecules"},{"issue":"125","key":"10.1016\/j.intimp.2023.110845_b0400","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neuropharm.2017.08.017","article-title":"GPR55: A therapeutic target for Parkinson's disease?","volume":"1","author":"Celorrio","year":"2017","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0405","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1017\/neu.2020.30","article-title":"The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson\u2019s disease rat model","volume":"33","author":"Fatemi","year":"2021","journal-title":"Acta neuropsychiatrica"},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-018-1362-7","article-title":"Anti-neuroinflammatory effects of GPR55 antagonists in LPS-activated primary microglial cells","volume":"15","author":"Saliba","year":"2018","journal-title":"J. Neuroinflammation"},{"issue":"112","key":"10.1016\/j.intimp.2023.110845_b0415","article-title":"Activation of GPR55 attenuates cognitive impairment and neurotoxicity in a mouse model of Alzheimer's disease induced by A\u03b21\u201342 through inhibiting RhoA\/ROCK2 pathway","volume":"10","author":"Xiang","year":"2022","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.intimp.2023.110845_b0420","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1021\/acschemneuro.8b00572","article-title":"Orphan receptor GPR88 as an emerging neurotherapeutic target","volume":"10","author":"Ye","year":"2018","journal-title":"ACS Chem. Nerosci."},{"issue":"3","key":"10.1016\/j.intimp.2023.110845_b0425","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1460-9568.2009.06842.x","article-title":"Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents","volume":"30","author":"Massart","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.intimp.2023.110845_b0430","unstructured":"Arefin TM.GPR88 signatures in mouse neuronal connectivity and behavior: a potential therapeutic target for psychiatric disorders(Doctoral dissertation, Universit\u00e9 de Strasbourg; Albert-Ludwigs-Universit\u00e4t (Freiburg im Breisgau, Allemagne))."},{"issue":"10","key":"10.1016\/j.intimp.2023.110845_b0435","first-page":"164","article-title":"Protection of primary dopaminergic midbrain neurons by GPR139 agonists supports different mechanisms of MPP+ and rotenone toxicity","volume":"28","author":"Bayer Andersen","year":"2016","journal-title":"Front. Cell. Neurosci."},{"issue":"13","key":"10.1016\/j.intimp.2023.110845_b0440","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.addr.2010.08.007","article-title":"Structural and functional insights into nuclear receptor signaling","volume":"62","author":"Jin","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.intimp.2023.110845_b0445","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/9781119436812.ch28","article-title":"Hepatic Nuclear Receptors","volume":"12","author":"Soccio","year":"2020","journal-title":"Liver: Biol. Pathobiol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110845_b0450","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/molecules25030725","article-title":"GPR6 structural insights: homology model construction and docking studies","volume":"25","author":"Isawi","year":"2020","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.intimp.2023.110845_b0455","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.3892\/mmr.2016.4948","article-title":"Role of neuroinflammation in neurodegenerative diseases","volume":"13","author":"Chen","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.intimp.2023.110845_b0460","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.neures.2009.09.383","article-title":"Gs-linked receptor GPR3 modulates proliferation and differentiation of cerebellar granule cell precursors","volume":"65","author":"Tanaka","year":"2009","journal-title":"Neurosci. Res."},{"issue":"79","key":"10.1016\/j.intimp.2023.110845_b0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neures.2013.10.004","article-title":"Neuroinflammation: the role and consequences","volume":"1","author":"Lyman","year":"2014","journal-title":"Neurosci. Res."},{"issue":"3","key":"10.1016\/j.intimp.2023.110845_b0470","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.molmed.2012.12.003","article-title":"Parkinson's disease in the nuclear age of neuroinflammation","volume":"19","author":"Nolan","year":"2013","journal-title":"Trends Mol. Med."},{"issue":"10","key":"10.1016\/j.intimp.2023.110845_b0475","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/acs.jmedchem.1c00028","article-title":"Novel approaches, drug candidates, and targets in pain drug discovery","volume":"64","author":"Obeng","year":"2021","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.intimp.2023.110845_b0480","doi-asserted-by":"crossref","first-page":"9592","DOI":"10.1021\/acs.jmedchem.1c00186","article-title":"Targeting nuclear receptors in neurodegeneration and neuroinflammation","volume":"64","author":"Willems","year":"2021","journal-title":"J. Med. Chem."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923011700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923011700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:04:42Z","timestamp":1761588282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923011700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":96,"alternative-id":["S1567576923011700"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110845","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuclear orphan receptors: A novel therapeutic agent in neuroinflammation","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110845","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110845"}}